Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Accenture
Healthtrust
McKinsey
QuintilesIMS
Merck
Chubb
Farmers Insurance
UBS

Generated: May 27, 2018

DrugPatentWatch Database Preview

SEVELAMER CARBONATE - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for sevelamer carbonate and what is the scope of sevelamer carbonate freedom to operate?

Sevelamer carbonate
is the generic ingredient in two branded drugs marketed by Genzyme, Aurobindo Pharma Ltd, Amneal Pharms Co, Dr Reddys Labs Ltd, Impax Labs Inc, Invagen Pharms, and Sandoz Inc, and is included in nine NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sevelamer carbonate has fifty-two patent family members in twenty-one countries.

There are thirty-two drug master file entries for sevelamer carbonate. Twenty suppliers are listed for this compound.
Pharmacology for SEVELAMER CARBONATE
Synonyms for SEVELAMER CARBONATE
2-Propen-1-amine polymer with (chloromethyl)oxirane carbonate
845273-93-0
9YCX42I8IU
ALLYLAMINE; CARBONIC ACID; EPICHLOROHYDRIN
AN-9605
Carbonic acid, compd. with (chloromethyl)oxirane polymer with 2-propen-1-amine
carbonic acid; 2-(chloromethyl)oxirane; prop-2-en-1-amine
D0G7XO
GT 335-012
GT-335-012
HE045749
HS-0081
KS-00002WUH
MolPort-035-869-714
Prop-2-en-1-amine polymer with (Chloromethyl)oxirane carbonate
Renvela
Renvela (powder formulation), Genzyme
SC-24770
Second generation sevelamer, Genzyme
Sevelamer carbonate (powder formulation, renal disease/hyperphosphatemia), Genzyme
Sevelamer carbonate (tablet, renal disease/hyperphosphatemia), Genzyme
Sevelamer carbonate [USAN]
Sevelamer carbonate tablet
UNII-9YCX42I8IU

US Patents and Regulatory Information for SEVELAMER CARBONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Amneal Pharms Co SEVELAMER CARBONATE sevelamer carbonate TABLET;ORAL 207288-001 Nov 28, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Impax Labs Inc SEVELAMER CARBONATE sevelamer carbonate TABLET;ORAL 090975-001 Oct 23, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for SEVELAMER CARBONATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-002 Feb 18, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-002 Feb 18, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for SEVELAMER CARBONATE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,808,738 Aliphatic amine polymer salts for tableting ➤ Try a Free Trial
9,585,911 Sachet formulation for amine polymers ➤ Try a Free Trial
9,895,315 Aliphatic amine polymer salts for tableting ➤ Try a Free Trial
9,555,056 Aliphatic amine polymer salts for tableting ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for SEVELAMER CARBONATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/011 United Kingdom ➤ Try a Free Trial PRODUCT NAME: SEVELAMER; REGISTERED: UK EU/1/99/120/001-004 20000202
C0011 France ➤ Try a Free Trial PRODUCT NAME: SEVELAMER; REGISTRATION NO/DATE: EU/1/99/123/001 20000128
00428 Netherlands ➤ Try a Free Trial PRODUCT NAME: SEVELAMER CARBONAAT OF BICARBONAAT; REGISTRATION NO/DATE: EU/1/09/521/001-007 20090610
2002 Austria ➤ Try a Free Trial PRODUCT NAME: SEVELAMER SOWIE DESSEN PHARMAZEUTISCH VERTRAEGLICHEN SALZE; REGISTRATION NO/DATE: EU/1/99/123/001 - EU/1/99/123/004 20000128
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Healthtrust
Merck
Argus Health
Harvard Business School
Federal Trade Commission
Queensland Health
Moodys
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.